Physician profile
Albert K Pierce
NPI 1841850377
$3,790.11
in general payments reported to CMS, 2019-2025
18 companies · $647 in 2025
The $647 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $284 · 2022: $480 · 2023: $282 · 2024: $2,097 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,979 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,979.02 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $1,755.10 | 2024 | Brainsway Deep Tms System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $384.58 | 2022-2025 | Caplyta |
| Alkermes, INC. | $332.87 | 2021-2025 | Lybalvi, Aristada |
| Abbvie INC. | $277.19 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $228.56 | 2022-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $217.12 | 2021-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Vanda Pharmaceuticals INC. | $107.50 | 2022-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $100.28 | 2021-2023 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $94.04 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $70.95 | 2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $66.78 | 2024-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $37.20 | 2025 | Cobenfy |
| Biogen, INC. | $27.57 | 2025 | Zurzuvae |
| Vertical Pharmaceuticals, LLC | $19.34 | 2025 | Relexxii |
| Indivior INC. | $19.15 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $18.99 | 2023 | Quviviq |
| Bausch Health US, LLC | $17.68 | 2025 | Aplenzin |
| Corium, LLC | $15.21 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.